In the following figure the User Scenario is presented in three different possible scenarios. In the first scenario a patient is treated for a heart arrhythmia and the cardiologist wants to validate if the treatment worked. In the second scenario a patient visits the general practitioner with pain on the chest. Instead of forwarding the patient directly to the cardiologist, the GP can execute this test to see if this is necessary. In the third scenario, the bracelet will be used in a research setting regarding Atrial Fibrillation.
Once a patient has been admitted to a hospital, they will be checked on by the nursing staff every four hours (even during the night). With nursing teams being overworked and understaffed, manual checks of patient vital signs and manual data entry may lead to errors and omissions. Corsano’s CardioWatch eliminates the need for manual data entry by syncing patient vital sign data directly into the EHR system via Device Hub. In addition, Corsano’s CardioWatch enables a much more peaceful and comfortable experience for patients. Patients can move around freely as well as sleep through the night without interruptions, which has been proven to lead to faster healing. All this whilst having the reassurance that the physician is making the best possible treatment decisions based on Corsano’s CardioWatch clinically validated cardiac vitals and core body temperature data.
Tens of millions of patients undergo major surgeries worldwide each year, and the post-operative phase carries a high risk of complications. Although current standard care includes vital sign observations at regular intervals, patients often deteriorate between measurements to the extent that they require admission to intensive care and/or prolonged hospital stay.
Current hospital practice means patients need to remain in hospital post-surgery or return regularly after discharge for follow-up appointments.
Corsano’s CardioWatch provides accurate and continuous monitoring of patients following surgery. For example, Corsano’s CardioWatch Bracelet allows physicians to better assess the risk of sepsis or an anaesthetic-related apnea event, which can often lead to longer hospital-stays, readmissions, and higher costs for both the patient and the provider. The better data provided by CardioWatch also gives care teams the confidence to get patients moving sooner, leading to faster recovery and earlier discharge.
Hospital at Home
Healthcare providers globally are beginning to shift patients towards homecare programs in order to reduce costs and improve outcomes by avoiding the dangers associated with hospital admission. Not only does home-based care offer greater mobility for patients but it also allows for community based early interventions to prevent readmissions.
With Corsano CardioWatch, healthcare professionals can receive complete and clinically accurate information about their patients’ health status directly from the patients’ homes. By effectively extending critical care pathways outside the hospital, patients can remain under the direct care of their consulting physicians and specialized care teams. Patient data and early warning alerts are communicated to personal mobile devices and the CardioWatch Health Cloud. With an open API they are integrated with the hospital’s EHR system.
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and its paroxysmal nature makes its detection challenging. CardioWatch 287 enables pulse wave extraction from the green light spectrum of the signal. RR intervals are automatically identified. For discrimination between AF and SR, we test three different statistical methods. For discrimination between AF and SR, ShE yields the highest sensitivity and specificity with 85 and 95%, respectively. Applying a tachogram filter results in an improved sensitivity of 87.5%, when combining ShE and nRMSSD, while specificity remained stable at 95%. A combination of SD1/SD2 index and nRMSSD leads to further improvement and results in a sensitivity and specificity of 95%.
Clinical trials are time consuming, costly, and resource intensive. Continuous and remote monitoring enable large data sets of accurate, continuous data that could provide new insights a myriad of physiological parameters for thousands of clinical trial participants.
Corsano’s CardioWatch collects real-time vital sign data to enable CRO’s to know the status of their clinical trial participants anytime, anywhere. This enables larger clinical trials, more accurate data, and reduced costs related to participants traveling to checkups and resources required to monitor participants.